COMPANY’S ULTRA-SENSITIVE PLATFORM CONTINUES TO FACILITATE IMPORTANT ADVANCES THAT HARNESS BIOMARKERS TO IDENTIFY, MONITOR AND VALIDATE TREATMENT PATHWAYS FOR MULTIPLE SCLEROSIS (MS)

Billerica, Mass. – (Business Wire) – Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that its ultra-sensitive Simoa® technology has been used by leading research teams to power 42 studies presented at the 8th Joint ACTRIMS-ECTRIMS Meeting, MSVirtual2020, taking place remotely from Sept. 11-13. Additionally, Quanterix will be sponsoring the event with a virtual exhibit booth. The 2020 event marks Quanterix’ fifth consecutive year of supporting MS research through its continued participation at this meeting and its third year as a sponsoring organization.

“Although the pandemic has shifted global attention to a different fight, chronic conditions like MS continue to impact the lives of millions,” said Kevin Hrusovsky, Chairman, Chief Executive Officer and President, Quanterix and Founder, Powering Precision Health (PPH). “We are grateful to the researchers who continue to advance their work during these uncertain times and are honored our Simoa technology continues to play an important role in powering these important breakthroughs. By applying the unprecedented sensitivity of our platform to their MS research, scientists have made significant strides toward diagnosing, monitoring and treating the disease that will be on full display this year.”

This year’s event will feature more than 40 Simoa-powered posters and presentations that look at various biomarkers used in the detection and treatment of neurodegenerative diseases – including serum neurofilament light (sNfL) – and evaluate how the biomarkers can be used to impact MS. Specifically, this year’s research presentations will focus on defining baseline levels of sNfL and how biomarkers are being used in MS monitoring and treatment in research and in the clinic.

Quanterix will also be participating in a special Encore event with Dr. David Leppert, Professor of Neurology at the University of Basel, based on his late-breaking abstract, “Neutrophil granulocyte markers in cerebrospinal fluid differentiate NMOSD and anti-MOG antibody associated disease from MS in acute disease phase,” on Saturday, Sept. 26. Dr. Leppert will illustrate how Simoa enabled his team to study biomarkers critical to distinguishing MS from Neuromyelitis Optica Spectrum Disorder (NMOSD) and anti-myelin oligodendrocyte glycoprotein (anti-MOG), two immune-mediated inflammatory conditions that require lengthy methods for differentiation using traditional cell-based laboratory methods.

Additional late-breaking abstracts include two manuscripts from Paola Valentino, a biotechnologist and specialist in clinical biochemistry at the Neuroscience Institute Cavalieri Ottolenghi, and one from Dr. Antonio Bertolotto, head physician and neurologist at San Luigi Gonzaga Hospital. Valentino will present, “Normal serum NfL levels: a proposal of cut-off strategy definition for the clinical practice” (LB1219), and “Real-life experience with sNfL in Multiple Sclerosis patients, as monitoring and treatment decision biomarker” (LB1220). Dr. Bertolotto will discuss the proposal, “Applicability of sNfL in Multiple Sclerosis as additional measure in clinical practice and implications in NEDA-3 evaluation” (LB1221).

Attendees are encouraged to visit Quanterix’ sponsored booth to speak with company experts about the advantages of Simoa technology along with its robust menu of ultra-sensitive, blood-based assays, including neurofilament light chain (NfL) and inflammatory cytokines, to support MS diagnosis, monitoring and treatment efforts. More information about Simoa’s MS capabilities will be displayed prominently in the MSVirtual Industry Hub alongside other sponsoring companies, such as Biogen, Novartis, Bristol Myers Squibb and EMD Serono.

To learn more about Quanterix’ involvement in the virtual meeting, visit https://www.quanterix.com/resources/conferences/actrimsectrims-2020. To find out more about Simoa® technology, visit https://www.quanterix.com/technology. To view its wide-range of neurology assays, click here.

About Quanterix

Quanterix is a company that’s digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s digital health solution, Simoa®, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts. For additional information, please visit https://www.quanterix.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’ filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Contacts

Media Contact:
PAN Communications
Staci Didner, (407) 734-7325
quanterix@pancomm.com

Investor Relations Contact:
Stephen Hrusovsky
(774) 278-0496
shrusovsky@quanterix.com